Hyperphosphorylation of BCL-2 family proteins underlies functional resistance to venetoclax in lymphoid malignanciesStephen Jun Fei Chong, Matthew S. Davids, Fen Zhu et al.|Journal of Clinical Investigation|2023Cited by 43
BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemiaCharles Herbaux, Matthew S. Davids, Christoph Kornauth et al.|Blood|2021Cited by 37
Updated Results from a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk DiseaseChristine E. Ryan, Matthew S. Davids, Samantha Pazienza et al.|Blood|2022Cited by 23
Hypomethylating agent decitabine sensitizes diffuse large B-cell lymphoma to venetoclaxFen Zhu, Matthew S. Davids, Jennifer L. Crombie et al.|Haematologica|2023Cited by 14
Abstract 5377: Decitabine sensitizes diffuse large B cell lymphoma cells to venetoclaxMatthew S. Davids, May C. Collins, Fen Zhu et al.|Cancer Research|2022Cited by 0